AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,260,000 shares, a decline of 25.4% from the December 15th total of 1,690,000 shares. Based on an average daily trading volume, of 370,200 shares, the days-to-cover ratio is currently 3.4 days.

AlloVir Price Performance

Shares of NASDAQ ALVR opened at $9.00 on Friday. AlloVir has a fifty-two week low of $7.96 and a fifty-two week high of $24.15. The firm has a market capitalization of $1.04 billion, a P/E ratio of -10.23 and a beta of 0.65. The company’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.69.

AlloVir (NASDAQ:ALVR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10.

Institutional Trading of AlloVir

An institutional investor recently raised its position in AlloVir stock. Cubist Systematic Strategies LLC raised its position in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,816 shares of the company’s stock after purchasing an additional 30,072 shares during the period. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent filing with the SEC. 66.05% of the stock is currently owned by institutional investors.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.